|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hudes G, Carducci M, Tomczak P, Dutcher J,
Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi
I, et al: Temsirolimus, interferon alfa, or both for advanced
renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Albiges L, Oudard S, Negrier S, Caty A,
Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, et
al: Complete remission with tyrosine kinase inhibitors in renal
cell carcinoma. J Clin Oncol. 30:482–487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mitchell AP, Hirsch BR, Harrison MR,
Abernethy AP and George DJ: Deferred systemic therapy in patients
with metastatic renal cell carcinoma. Clin Genitourin Cancer.
13:e159–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Rini BI, McDermott DF, Arén
Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B,
Beuselinck B, Amin A, et al: Nivolumab plus ipilimumab versus
sunitinib in first-line treatment for advanced renal cell
carcinoma: Extended follow-up of efficacy and safety results from a
randomised, controlled, phase 3 trial. Lancet Oncol. 20:1370–1385.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Powles T, Plimack ER, Soulières D, Waddell
T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko
I, et al: Pembrolizumab plus axitinib versus sunitinib monotherapy
as first-line treatment of advanced renal cell carcinoma
(KEYNOTE-426): Extended follow-up from a randomised, open-label,
phase 3 trial. Lancet Oncol. 21:1563–1573. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uemura M, Tomita Y, Miyake H, Hatakeyama
S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, et
al: Avelumab plus axitinib vs sunitinib for advanced renal cell
carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Cancer Sci. 111:907–923. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martins F, Sofiya L, Sykiotis GP, Lamine
F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A,
Guex-Crosier Y, et al: Adverse effects of immune-checkpoint
inhibitors: Epidemiology, management and surveillance. Nat Rev Clin
Oncol. 16:563–580. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang M, Firrman J, Liu L and Yam K: A
review on flavonoid apigenin: Dietary intake, ADME, antimicrobial
effects, and interactions with human gut microbiota. Biomed Res
Int. 2019:70104672019.PubMed/NCBI
|
|
11
|
Salehi B, Venditti A, Sharifi-Rad M,
Kręgiel D, Sharifi-Rad J, Durazzo A, Lucarini M, Santini A, Souto
EB, Novellino E, et al: The therapeutic potential of apigenin. Int
J Mol Sci. 20:13052019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shukla S and Gupta S: Apigenin: A
promising molecule for cancer prevention. Pharm Res. 27:962–978.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou Y, Zheng J, Li Y, Xu DP, Li S, Chen
YM and Li HB: Natural polyphenols for prevention and treatment of
cancer. Nutrients. 8:5152016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Patel D, Shukla S and Gupta S: Apigenin
and cancer chemoprevention: Progress, potential and promise
(review). Int J Oncol. 30:233–245. 2007.PubMed/NCBI
|
|
15
|
Lu HF, Chie YJ, Yang MS, Lee CS, Fu JJ,
Yang JS, Tan TW, Wu SH, Ma YS, Ip SW, et al: Apigenin induces
caspase-dependent apoptosis in human lung cancer A549 cells through
Bax- and Bcl-2-triggered mitochondrial pathway. Int J Oncol.
36:1477–1484. 2010.PubMed/NCBI
|
|
16
|
Ganai SA: Plant-derived flavone Apigenin:
The small-molecule with promising activity against therapeutically
resistant prostate cancer. Biomed Pharmacother. 85:47–56. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shukla S, MacLennan GT, Flask CA, Fu P,
Mishra A, Resnick MI and Gupta S: Blockade of beta-catenin
signaling by plant flavonoid apigenin suppresses prostate
carcinogenesis in TRAMP mice. Cancer Res. 67:6925–6935. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ruela-de-Sousa RR, Fuhler GM, Blom N,
Ferreira CV, Aoyama H and Peppelenbosch MP: Cytotoxicity of
apigenin on leukemia cell lines: Implications for prevention and
therapy. Cell Death Dis. 1:e192010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee HH, Jung J, Moon A, Kang H and Cho H:
Antitumor and anti-invasive effect of apigenin on human breast
carcinoma through suppression of IL-6 expression. Int J Mol Sci.
20:31432019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ujiki MB, Ding XZ, Salabat MR, Bentrem DJ,
Golkar L, Milam B, Talamonti MS, Bell RH Jr, Iwamura T and Adrian
TE: Apigenin inhibits pancreatic cancer cell proliferation through
G2/M cell cycle arrest. Mol Cancer. 5:762006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maggioni D, Garavello W, Rigolio R,
Pignataro L, Gaini R and Nicolini G: Apigenin impairs oral squamous
cell carcinoma growth in vitro inducing cell cycle arrest and
apoptosis. Int J Oncol. 43:1675–1682. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gupta S, Afaq F and Mukhtar H: Selective
growth-inhibitory, cell-cycle deregulatory and apoptotic response
of apigenin in normal versus human prostate carcinoma cells.
Biochem Biophys Res Commun. 287:914–920. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiang LC, Ng LT, Lin IC, Kuo PL and Lin
CC: Anti-proliferative effect of apigenin and its apoptotic
induction in human Hep G2 cells. Cancer Lett. 237:207–214. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu XX, Mizutani Y, Kakehi Y, Yoshida O and
Ogawa O: Enhancement of Fas-mediated apoptosis in renal cell
carcinoma cells by adriamycin. Cancer Res. 60:2912–2918.
2000.PubMed/NCBI
|
|
25
|
Jin X, Wu XX, Abdel-Muneem Nouh MA and
Kakehi Y: Enhancement of death receptor 4 mediated apoptosis and
cytotoxicity in renal cell carcinoma cells by subtoxic
concentrations of doxorubicin. J Urol. 177:1894–1899. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu XX, Jin XH, Zeng Y, El Hamed AM and
Kakehi Y: Low concentrations of doxorubicin sensitizes human solid
cancer cells to tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing
TRAIL-R2 expression. Cancer Sci. 98:1969–1976. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Coppin C, Le L, Porzsolt F and Wilt T:
Targeted therapy for advanced renal cell carcinoma. Cochrane
Database Syst Rev. Cd0060172008.PubMed/NCBI
|
|
28
|
Zhou L, Liu XD, Sun M, Zhang X, German P,
Bai S, Ding Z, Tannir N, Wood CG, Matin SF, et al: Targeting MET
and AXL overcomes resistance to sunitinib therapy in renal cell
carcinoma. Oncogene. 35:2687–2697. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang W, Heideman L, Chung CS, Pelling JC,
Koehler KJ and Birt DF: Cell-cycle arrest at G2/M and growth
inhibition by apigenin in human colon carcinoma cell lines. Mol
Carcinog. 28:102–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim SM, Vetrivel P, Ha SE, Kim HH, Kim JA
and Kim GS: Apigetrin induces extrinsic apoptosis, autophagy and
G2/M phase cell cycle arrest through PI3K/AKT/mTOR pathway in AGS
human gastric cancer cell. J Nutr Biochem. 83:1084272020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shendge AK, Chaudhuri D and Mandal N: The
natural flavones, acacetin and apigenin, induce Cdk-Cyclin mediated
G2/M phase arrest and trigger ROS-mediated apoptosis in
glioblastoma cells. Mol Biol Rep. 48:539–549. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shendge AK, Chaudhuri D, Basu T and Mandal
N: A natural flavonoid, apigenin isolated from Clerodendrum
viscosum leaves, induces G2/M phase cell cycle arrest and apoptosis
in MCF-7 cells through the regulation of p53 and caspase-cascade
pathway. Clin Transl Oncol. 23:718–730. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meng S, Zhu Y, Li JF, Wang X, Liang Z, Li
SQ, Xu X, Chen H, Liu B, Zheng XY, et al: Apigenin inhibits renal
cell carcinoma cell proliferation. Oncotarget. 8:19834–19842. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Norbury C and Nurse P: Animal cell cycles
and their control. Annu Rev Biochem. 61:441–470. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morla AO, Draetta G, Beach D and Wang JY:
Reversible tyrosine phosphorylation of cdc2: dephosphorylation
accompanies activation during entry into mitosis. Cell. 58:193–203.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jessus C and Beach D: Oscillation of MPF
is accompanied by periodic association between cdc25 and
cdc2-cyclin B. Cell. 68:323–332. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamada S, Sumrejkanchanakij P, Amagasa T
and Ikeda MA: Loss of cyclin E requirement in cell growth of an
oral squamous cell carcinoma cell line implies deregulation of its
downstream pathway. Int J Cancer. 111:17–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choi EJ and Kim GH: Apigenin causes G(2)/M
arrest associated with the modulation of p21(Cip1) and Cdc2 and
activates p53-dependent apoptosis pathway in human breast cancer
SK-BR-3 cells. J Nutr Biochem. 20:285–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Piantelli M, Rossi C, Iezzi M, La Sorda R,
Iacobelli S, Alberti S and Natali PG: Flavonoids inhibit melanoma
lung metastasis by impairing tumor cells endothelium interactions.
J Cell Physiol. 207:23–29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li J, Tan G, Cai Y, Liu R, Xiong X, Gu B,
He W, Liu B, Ren Q, Wu J, et al: A novel Apigenin derivative
suppresses renal cell carcinoma via directly inhibiting wild-type
and mutant MET. Biochem Pharmacol. 190:1146202021. View Article : Google Scholar : PubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBI
|
